NO971868L - Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom - Google Patents

Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom

Info

Publication number
NO971868L
NO971868L NO971868A NO971868A NO971868L NO 971868 L NO971868 L NO 971868L NO 971868 A NO971868 A NO 971868A NO 971868 A NO971868 A NO 971868A NO 971868 L NO971868 L NO 971868L
Authority
NO
Norway
Prior art keywords
difficile
antitoxin
antitoxins
treatment
humans
Prior art date
Application number
NO971868A
Other languages
English (en)
Other versions
NO323305B1 (no
NO971868D0 (no
Inventor
James A Williams
Nisha V Padhye
John A Kink
Bruce S Thalley
Douglas C Stafford
Joseph R Firca
Original Assignee
Ophidian Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/405,496 external-priority patent/US5919665A/en
Priority claimed from US08/480,604 external-priority patent/US5736139A/en
Application filed by Ophidian Pharm Inc filed Critical Ophidian Pharm Inc
Publication of NO971868D0 publication Critical patent/NO971868D0/no
Publication of NO971868L publication Critical patent/NO971868L/no
Publication of NO323305B1 publication Critical patent/NO323305B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19971868A 1994-10-24 1997-04-23 Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det. NO323305B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32915494A 1994-10-24 1994-10-24
US08/405,496 US5919665A (en) 1989-10-31 1995-03-16 Vaccine for clostridium botulinum neurotoxin
US42271195A 1995-04-14 1995-04-14
US08/480,604 US5736139A (en) 1989-10-31 1995-06-07 Treatment of Clostridium difficile induced disease
PCT/US1995/013737 WO1996012802A1 (en) 1989-10-31 1995-10-23 Vaccine and antitoxin for treatment and prevention of c. difficile disease

Publications (3)

Publication Number Publication Date
NO971868D0 NO971868D0 (no) 1997-04-23
NO971868L true NO971868L (no) 1997-06-24
NO323305B1 NO323305B1 (no) 2007-03-05

Family

ID=27502393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971868A NO323305B1 (no) 1994-10-24 1997-04-23 Opploselig rekombinant botulinum-toksin og farmasoytisk preparat som inneholder det.

Country Status (17)

Country Link
US (1) US6290960B1 (no)
EP (2) EP1041149B8 (no)
JP (2) JP2002514886A (no)
CN (1) CN1176658A (no)
AT (1) ATE366312T1 (no)
AU (1) AU709586B2 (no)
BR (1) BR9509903A (no)
CA (1) CA2203504A1 (no)
CZ (1) CZ296806B6 (no)
DE (1) DE69535530D1 (no)
FI (1) FI971732A (no)
HU (1) HUT78048A (no)
MX (1) MX9702955A (no)
NO (1) NO323305B1 (no)
NZ (2) NZ295998A (no)
PL (1) PL320214A1 (no)
WO (1) WO1996012802A1 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US8012491B2 (en) 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
WO1998008540A1 (en) * 1996-08-28 1998-03-05 Ophidian Pharmaceuticals, Inc. Multivalent vaccine for clostridium botulinum neurotoxin
AR010218A1 (es) * 1996-09-10 2000-06-07 Military Henry M Jackson Foundation For The Advancement Of Una familia de proteinas bacterianas multi-unidad
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US7179611B2 (en) * 1997-02-10 2007-02-20 Bd Lee Laboratories Mono-specific polyclonal antibodies and methods for detecting Clostridium difficile Toxin A
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
CA2307331C (en) 1997-10-20 2017-03-21 Oravax, Inc. Passive immunization against clostridium difficile disease
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6780617B2 (en) 2000-12-29 2004-08-24 Chen & Chen, Llc Sample processing device and method
WO2000002902A1 (en) * 1998-07-13 2000-01-20 Gill Parkash S Novel inhibitors of angiogenesis and tumor growth
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
WO2000061762A1 (en) * 1999-04-09 2000-10-19 Techlab, Inc. RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
FR2796385A1 (fr) * 1999-07-16 2001-01-19 Inst Nat Sante Rech Med Methode de production d'anticorps dans le jaune d'oeuf et utilisation des anticorps ainsi obtenus
GB9921592D0 (en) 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
JP4513085B2 (ja) 2001-09-11 2010-07-28 アイキューム インク 試料の容器
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2004220626B2 (en) 2003-02-05 2010-07-29 Iquum Inc. Sample processing tubule
US9701737B2 (en) * 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
NZ580828A (en) 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
EP1773874B1 (en) * 2004-08-04 2012-10-24 Allergan, Inc. Optimizing expression of active botulinum toxin type a
JP5308029B2 (ja) * 2004-11-24 2013-10-09 テクラブ インコーポレイテッド 分析物を検出するための装置および方法
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
CN100564527C (zh) * 2006-10-23 2009-12-02 中国人民解放军军事医学科学院生物工程研究所 A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
JP5305427B2 (ja) * 2007-01-11 2013-10-02 公立大学法人大阪府立大学 インフルエンザウイルスに対する抗体の産生方法
JP2008169142A (ja) * 2007-01-11 2008-07-24 Osaka Prefecture Univ 食中毒菌に対する抗体の産生方法
WO2010135585A2 (en) * 2009-05-20 2010-11-25 University Of Maryland, Baltimore Engineered type iv pilin of clostridium difficile
US9802988B2 (en) 2009-05-20 2017-10-31 University Of Maryland, Baltimore Engineered type IV pilin of Clostridium difficile
CA2782406A1 (en) * 2009-12-02 2011-06-09 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP6121421B2 (ja) * 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
CN102181457B (zh) * 2011-03-21 2012-07-04 王世霞 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗
SI2699587T1 (sl) 2011-04-22 2019-08-30 Wyeth Llc Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka
SI2714910T1 (en) 2011-05-27 2018-04-30 Glaxosmithkline Biologicals Sa An immunogenic composition
WO2013082298A2 (en) * 2011-11-30 2013-06-06 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
RU2014127714A (ru) * 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
PT3513806T (pt) 2012-12-05 2023-03-02 Glaxosmithkline Biologicals Sa Composição imunogénica
CN103865938B (zh) * 2012-12-16 2016-10-05 山东国际生物科技园发展有限公司 艰难梭菌外毒素a羧基端序列密码子优化基因片段、表达载体构建方法及其表达蛋白的应用
EP2969012A4 (en) 2013-03-12 2016-09-14 Univ Yale COMPOSITIONS AND METHODS FOR IDENTIFYING MICROBES RELATED TO SECRETORY ANTIBODIES
EP3636278A3 (en) 2014-06-25 2020-07-15 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
WO2016033439A2 (en) * 2014-08-28 2016-03-03 Yale University Compositions and methods for the treating an inflammatory disease or disorder
EP3791859A1 (en) 2015-06-12 2021-03-17 Vaxart, Inc. Formulations for small intestinal delivery of rsv and norovirus antigens
US10617650B2 (en) * 2015-10-16 2020-04-14 Merck Sharp & Dohme Corp. Process for preparing formulations for gastrointestinal-targeted therapies
JP6964623B2 (ja) * 2017-03-29 2021-11-10 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
JP6612807B2 (ja) * 2017-03-29 2019-11-27 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
CN108822211B (zh) * 2018-06-05 2019-12-24 中国人民解放军军事科学院军事医学研究院 一种制备a、b、e、f型四价肉毒抗毒素的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
EP0225254B1 (en) 1985-11-25 1994-03-16 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5268295A (en) * 1991-05-31 1993-12-07 W. Alton Jones Cell Science Center, Inc. Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
EP0659214A1 (en) * 1992-09-01 1995-06-28 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
JPH06192118A (ja) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
JPH06192296A (ja) * 1992-10-28 1994-07-12 Chiba Pref Gov 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。
US5480972A (en) * 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen

Also Published As

Publication number Publication date
EP0796326A4 (en) 2000-01-19
JP2002514886A (ja) 2002-05-21
FI971732A (fi) 1997-06-23
JP2003137897A (ja) 2003-05-14
HUT78048A (hu) 1999-07-28
EP1041149B8 (en) 2007-10-03
NO323305B1 (no) 2007-03-05
CN1176658A (zh) 1998-03-18
CA2203504A1 (en) 1996-05-02
FI971732A0 (fi) 1997-04-23
PL320214A1 (en) 1997-09-15
EP0796326A1 (en) 1997-09-24
WO1996012802A1 (en) 1996-05-02
EP1041149A3 (en) 2001-05-02
EP1041149A2 (en) 2000-10-04
MX9702955A (es) 1998-07-31
ATE366312T1 (de) 2007-07-15
DE69535530D1 (de) 2007-08-16
JP3914484B2 (ja) 2007-05-16
AU3968395A (en) 1996-05-15
US6290960B1 (en) 2001-09-18
WO1996012802A9 (en) 1999-09-16
BR9509903A (pt) 1997-11-25
AU709586B2 (en) 1999-09-02
EP1041149B1 (en) 2007-07-04
NZ295998A (en) 1999-10-28
CZ125097A3 (cs) 1998-03-18
NO971868D0 (no) 1997-04-23
NZ337543A (en) 2002-06-28
CZ296806B6 (cs) 2006-06-14

Similar Documents

Publication Publication Date Title
NO971868L (no) Vaksine og antitoksin for behandling og forhindring av C.difficile-sykdom
DK534188D0 (da) Hidtil ukendt vaccine
DK1372708T3 (da) Vaccine til transkutan immunisering mod rejsediarre
NO20004972L (no) Derivater av pneumokokkale kolinbindende proteiner for vaksiner
AU7814498A (en) Multivalent (in ovo) avian vaccine
ATE347376T1 (de) Behandlung von allergien
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
CA2022420A1 (en) Escherichia coli vaccine
CY1107188T1 (el) Εμβολιο ε. coli πτηνου για την προστασια εναντι κολοβακτηριωσης
WO2001034189A3 (en) Vaccines for mycoplasma bovis and methods of use
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
PT600396E (pt) Vacinas contra protozoarios intestinais
ATE435028T1 (de) Impfstoff gegen neisseria infektion
NO307815B1 (no) Levende eller inaktivert parental vaksine mot rotavirusinfeksjon
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
DK0535740T3 (da) Vaccine mod luftvejsinfektioner hos katte
DE69102649T2 (de) Hrsv-vakzine.
RU2285539C2 (ru) Молекулярная бивалентная вакцина для профилактики бруцеллеза и диарей, вызванных энтеропатогенными бактериями
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
HUP0003164A2 (hu) A Helicobacter pylori FlgE polipeptidet tartalmazó vakcinakészítmények
EA202100185A2 (ru) Вакцина и способ повышения иммуногенности и специфической активности средств профилактики инфекций
Mirchamsy et al. Oral Immunization against Diphtheria and Tetanus Infections by Fluid Dphtheria and Tetanus Toxoids
RU96123906A (ru) Способ и вакцина для профилактики и лечения иммунодефицитов, например рака